TSHA

Taysha Gene Therapies, Inc.

Healthcare
Biotechnology
$1.61B market cap

Forecast run · Sep 14, 2026Upside rank 530 of 3,136

Model Signal

ForecastQ Daily Probabilities

54.9%

21.2%

31.6%

Analyst Consensus

Recommendation2.17/5 Buy

Last price$5.02

Price target$14.00

Implied move+178.9%

Analysts18

ForecastQ Portfolios

TSHA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.